121 related articles for article (PubMed ID: 7690710)
1. Resistance of NIH3T3 cells to v-fes transformation induced by a dominant negative H-ras mutant.
Ogiso Y; Yokoyama T; Watari H; Shih TY; Kuzumaki N
Exp Cell Res; 1993 Oct; 208(2):415-21. PubMed ID: 7690710
[TBL] [Abstract][Full Text] [Related]
2. Transformation by Raf and other oncogenes renders cells differentially sensitive to growth inhibition by a dominant negative c-jun mutant.
Rapp UR; Troppmair J; Beck T; Birrer MJ
Oncogene; 1994 Dec; 9(12):3493-8. PubMed ID: 7970709
[TBL] [Abstract][Full Text] [Related]
3. trans-Dominant suppressor mutations of the H-ras oncogene.
Ogiso Y; Gutierrez L; Wrathall LS; Lu YY; Blair DG; Clanton DJ; Hwang YW; Shih TY
Cell Growth Differ; 1990 May; 1(5):217-24. PubMed ID: 2150753
[TBL] [Abstract][Full Text] [Related]
4. Isolation of a new class of 'flat' revertants from ras-transformed NIH3T3 cells using cis-4-hydroxy-L-proline.
Yanagihara K; Ciardiello F; Talbot N; McGeady ML; Cooper H; Benade L; Salomon DS; Bassin RH
Oncogene; 1990 Aug; 5(8):1179-86. PubMed ID: 2202950
[TBL] [Abstract][Full Text] [Related]
5. R-Ras induces malignant, but not morphologic, transformation of NIH3T3 cells.
Cox AD; Brtva TR; Lowe DG; Der CJ
Oncogene; 1994 Nov; 9(11):3281-8. PubMed ID: 7936652
[TBL] [Abstract][Full Text] [Related]
6. A dominant suppressive mutation in a cellular gene restores the nontransformed phenotype to v-fms-transformed mink cells.
Kato J; Sherr CJ
Oncogene; 1991 May; 6(5):687-93. PubMed ID: 2052353
[TBL] [Abstract][Full Text] [Related]
7. H-ras and raf-1 cooperate in transformation of NIH3T3 fibroblasts.
Cuadrado A; Bruder JT; Heidaran MA; App H; Rapp UR; Aaronson SA
Oncogene; 1993 Sep; 8(9):2443-8. PubMed ID: 8361757
[TBL] [Abstract][Full Text] [Related]
8. Retroviral gene transfer of dominant negative raf-1 mutants suppresses ha-ras-induced transformation and delays tumor formation.
Heinicke T; Radziwill G; Nawrath M; Rommel C; Pavlovic J; Moelling K
Cancer Gene Ther; 2000 May; 7(5):697-706. PubMed ID: 10830717
[TBL] [Abstract][Full Text] [Related]
9. Raf revertant cells resist transformation by non-nuclear oncogenes and are deficient in the induction of early response genes by TPA and serum.
Kolch W; Heidecker G; Troppmair J; Yanagihara K; Bassin RH; Rapp UR
Oncogene; 1993 Feb; 8(2):361-70. PubMed ID: 8426742
[TBL] [Abstract][Full Text] [Related]
10. Dominant inhibitory Ras mutants demonstrate the requirement for Ras activity in the action of tyrosine kinase oncogenes.
Stacey DW; Roudebush M; Day R; Mosser SD; Gibbs JB; Feig LA
Oncogene; 1991 Dec; 6(12):2297-304. PubMed ID: 1766676
[TBL] [Abstract][Full Text] [Related]
11. A role for Ras in v-Crk transformation.
Greulich H; Hanafusa H
Cell Growth Differ; 1996 Nov; 7(11):1443-51. PubMed ID: 8930393
[TBL] [Abstract][Full Text] [Related]
12. Cell lines containing and expressing the human herpesvirus 6A ts gene are protected from both H-ras and BPV-1 transformation.
Araujo JC; Doniger J; Stöppler H; Sadaie MR; Rosenthal LJ
Oncogene; 1997 Feb; 14(8):937-43. PubMed ID: 9050993
[TBL] [Abstract][Full Text] [Related]
13. A novel human ERK phosphatase regulates H-ras and v-raf signal transduction.
Shin DY; Ishibashi T; Choi TS; Chung E; Chung IY; Aaronson SA; Bottaro DP
Oncogene; 1997 Jun; 14(22):2633-9. PubMed ID: 9178761
[TBL] [Abstract][Full Text] [Related]
14. Suppression of malignant growth potentials of v-Src-transformed human gallbladder epithelial cells by adenovirus-mediated dominant negative H-Ras.
Tokumitsu Y; Nakano S; Ueno H; Niho Y
J Cell Physiol; 2000 May; 183(2):221-7. PubMed ID: 10737897
[TBL] [Abstract][Full Text] [Related]
15. C127 cells resistant to transformation by tyrosine protein kinase oncogenes.
Cuadrado A; Talbot N; Barbacid M
Cell Growth Differ; 1990 Jan; 1(1):9-15. PubMed ID: 2150330
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of oncogene-mediated transformation by ectopic expression of p21Waf1 in NIH3T3 cells.
Michieli P; Li W; Lorenzi MV; Miki T; Zakut R; Givol D; Pierce JH
Oncogene; 1996 Feb; 12(4):775-84. PubMed ID: 8632899
[TBL] [Abstract][Full Text] [Related]
17. Rit, a non-lipid-modified Ras-related protein, transforms NIH3T3 cells without activating the ERK, JNK, p38 MAPK or PI3K/Akt pathways.
Rusyn EV; Reynolds ER; Shao H; Grana TM; Chan TO; Andres DA; Cox AD
Oncogene; 2000 Sep; 19(41):4685-94. PubMed ID: 11032018
[TBL] [Abstract][Full Text] [Related]
18. Ras-interacting domain of Ral GDP dissociation stimulator like (RGL) reverses v-Ras-induced transformation and Raf-1 activation in NIH3T3 cells.
Okazaki M; Kishida S; Murai H; Hinoi T; Kikuchi A
Cancer Res; 1996 May; 56(10):2387-92. PubMed ID: 8625316
[TBL] [Abstract][Full Text] [Related]
19. Transformation-resistant mos revertant is unable to activate MAP kinase kinase in response to v-mos or v-raf.
Topol LZ; Marx M; Calothy G; Blair DG
Cell Growth Differ; 1995 Jan; 6(1):27-38. PubMed ID: 7718484
[TBL] [Abstract][Full Text] [Related]
20. Transformation suppressor activity of C3G is independent of its CDC25-homology domain.
Guerrero C; Fernandez-Medarde A; Rojas JM; Font de Mora J; Esteban LM; Santos E
Oncogene; 1998 Feb; 16(5):613-24. PubMed ID: 9482107
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
